DECN TO COMMENT AND PROVIDE ATTACK PLAN AFTER RECENT COURT RULING

DECN TO COMMENT AND PROVIDE ATTACK PLAN AFTER RECENT COURT RULING

Westlake Village, CA -- October 29, 2018 -- InvestorsHub NewsWire -- Decision Diagnostics Corp. (OTC PINK: DECN) is a 16 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the internationally launched GenSure! ("Feather") diabetes test strip, and the clinical trial in process GenChoice! ("Ladybug").  The company also markets the PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system, the imminently ready PetUltimate! Test strip and Avantage! Meter set for commercial launch in November 2018, and the panacea GenPrecis! ("Dragonfly") diabetes testing system, ready for clinical trials, will provide comments and an attack plan as soon as is practicable.

Keith Berman, CEO of Decision Diagnostics commented, "We are putting the final words to our plan of action, and will present this plan to shareholders and other interested parties this week."

Forward-Looking Statements:
This release contains the company's forward-looking statements which are based on management's current expectations and assumptions as of October 29, 2018, regarding the company's business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.

CONTACT INFORMATION:
Decision Diagnostics Corp.         
Keith Berman [phone]    
[e-mail]
www.genultimate.com
www.petsureteststrips.com
www.pharmatechdirect.com

SOURCE: Decision Diagnostics Corp.